González CR, Bustamante RY, Toranzo LR, Hernández MJ

Language: Spanish
References: 16
Page: 1718-1723
PDF size: 169.50 Kb.

ABSTRACT

A descriptive and cross-sectional study was carried out in 25 patients with terminal chronic renal failure treated with hemodial ysis in "Dr. Juan Bruno Zayas Alfonso" General Teaching Hospital of Santiago de Cu ba during 2006 in order to characterize the incidence of hepatitis C virus. Transfus ions in males (65.4 %), those who suffered from the disease for more than five years an d those that had been transfused in more than 10 times prevailed in the case ma terial. There was a higher number of transfusions in patients who had more time on hemodyalisis. It is concluded that this virus has a high incidence in patients polytransfused.

REFERENCES

1. Guirao AA, Yuste SR, Regueiro BJ. Epidemiología y manifestaciones clínicas de las hepatitis virales. Enf Infecc Microbiol Clin. 2006; 24:264-76.

2. Patel K, Muir AJ, Mc Hutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ. 2006; 332:1013-17.

3. Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother. 2006; 40(1):74-82.

4. Valtiville R, Moretto H, Lef l. Decline of high hepatitis c. Virus prevalence in a hemodyalisis unit with isolation measures during a 6- year follow up. Clin Nephrol. 2002; 57:371-5.

5. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3:47-52.

6. Narasimhan G, Sargios TN, Kalakuntla R, Homel P, Clain DJ, Theise ND, et al. Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat. 2006; 13(11):783-6.

7. World Health Organization. Hepatitis C [citado 12 May 2011]. Disponible en: http://www.who.int/csr/disease/hepatitis/Hepc.pdf

8. Asian Pacific Association for the Study of the Liver (APASL), Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007; 22(5):615-33.

9. Bruguera M, Forns X. Hepatitis C en España. Med Clin (Barc). 2006; 127:113-7.

10. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME, et al. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat. 2007; 14(3):213-20.

11. Programa hemoterapia, banco de sangre PRONAHEBAS, seroprevalencia a marcadores serológicos de hepatitis viral en donantes de sangre. Informe anual. Lima: MINSA; 2000.

12. Sanchez JL, Sjogren MH, Callahan JD, Watts DM, Lucas C, Abdel-Hamid M, et al. Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Trop Med Hyg. 2000; 63(5-6): 242-8.

13. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004; 12:96-102.

14. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia and vasculitis: immune complex relations. Lancet Infect Dis. 2005; 5:227-36.

15. Fabrizi F, Martin P, Dixit V, Bresina M, Russell J, Conrad A, et al. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Am J Nephrol. 1999; 19(3):383-8.

16. Di Lallo D, Miceli M, Petrosillo N, Perucci CA, Moscatelli M. Risk factors of hepatitis C virus infection in patients on hemodialysis. A multivariate analysis based on a dialysis register in Central Italy. Eur J Epidemiol 1999; 15(1)11-14.